In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

The global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a value of USD 294.4 ...

A new study has unveiled when chronic myeloid leukaemia, a type of cancer that affects the blood and bone marrow, arises in ...

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Discover the facts about throat cancer symptoms, prevention tips, and breakthrough treatments giving patients new hope for ...

Cancer Monoclonal Antibody Market Cancer rates continue to rise, especially in aging populations and areas affected by pollution and lifest ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Cancer Stem Cell Market Cancer stem cells (CSCs) are a distinct subset of tumor cells with stem-like properties, including self-renewal and ...